Drugs / SCO-120
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04942054 | May 2022 → Feb 2023 | hormone receptor-positive breast cancer | Sun Pharma Advanced Research Company Limited | Terminated | No outcome recorded |
| Phase 1 | NCT04242953 | Mar 2020 → Oct 2022 | — | Sun Pharma Advanced Research Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCO-120 | “A Phase 1 Study to Determine Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SCO-120 in Hormone Receptor Positive, HER-2 Negative Advanced...” NCT04942054 ↗ |
| Route | Oral | “single oral administration” NCT04242953 ↗ |